ERBB2 and breast cancer: These studies were not robust, however, and were too small to formulate guidelines. Current randomized stage III trials by the National Cancer Institute (NCI) to investigate the efficacy of carvedilol in preventing cardiac toxicity in patients with metastatic Her-2 positive breast cancer are ongoing.